Valganciclovir clinical trials
Also written Valcyte.
A product of Ganciclovir; its studies count on that page too.
How each study uses Valganciclovir is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Valganciclovir studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 29 Mar 2001 · VALCYTE · NDA 021304 (FDA, Drugs@FDA)
- European Union
- 18 Mar 1997 · Vitrasert Implant · EMEA/H/C/000120 (EMA; as Ganciclovir; now withdrawn)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
74 studies that test it; most in 2004 (8)
| Year | Studies |
|---|---|
| 1997 | 1 |
| 2000 | 1 |
| 2001 | 2 |
| 2002 | 3 |
| 2003 | 4 |
| 2004 | 8 |
| 2005 | 3 |
| 2006 | 7 |
| 2007 | 1 |
| 2008 | 4 |
| 2009 | 1 |
| 2010 | 2 |
| 2011 | 5 |
| 2012 | 4 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 4 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 4 |
| 2019 | 3 |
| 2020 | 2 |
| 2021 | 3 |
| 2024 | 3 |
| 2025 | 2 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 21 · Other 55
Hoffmann-La Roche (11) · National Institute of Allergy and Infectious Diseases (NIAID) (6) · University of California, San Francisco (4) · Viracta Therapeutics, Inc. (3) · National Cancer Institute (NCI) (2) · Dr. Ann C.T.M. Vossen (2) · Dr. Reddy's Laboratories Limited (2) · University of Washington (2)
Often tested with
Tested in the same studies.
Nanatinostat (3) · Zidovudine (2) · Bortezomib (2) · Mycophenolic Acid (2) · Valacyclovir (2) · Acyclovir (2) · Brincidofovir (2) · Everolimus (2)
Related medicines
As reviewed, each with the page that says it.
- A salt or form of Ganciclovir source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 1 phase 3 study under way
Valganciclovir is the comparator. A study of two new drugs counts under both.
- 1Letermovir · Columbia University · next primary completion Jan 2028
Reaching primary completion within a year · 4
Studies that test Valganciclovir.
- Nov 2026Efficacy and Safety of Leymovir Versus Valganciclovir in Prevention of Cytomegalovirus Infection and Cytomegalovirus Disease in Chinese Kidney Transplant RecipientsPhase 4 · First Affiliated Hospital Xi'an Jiaotong University
- Feb 2027ValgaNciclovIR for CMV Viraemia in AdvaNced HIV diseAsePhase 2 · Wits Health Consortium (Pty) Ltd
- May 2027CMV Immunity Monitoring in Lung Transplant RecipientsPhase 2 · NYU Langone Health
- Sep 2027A Clinical Trial Evaluating the Efficacy of Valganciclovir in Glioblastoma PatientsPhase 2 · Cecilia Soderberg-Naucler
Studies
Open first, then newest update. How each study uses Valganciclovir is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 76
- Kidney Transplant Preemptive Therapy or Prophylaxis for CMV Prevention in D+R RecipientsRecruitingPhase 3University of California, San FranciscoNCT06798909Written as Valganciclovir (Pre-emptive CMV Therapy)How we know
- Systemic and Topical Antiviral Control of Cytomegalovirus Anterior Uveitis: Treatment Outcomes - Trials I and IINot yet recruitingPhase 2University of California, San FranciscoNCT07513623Written as ValganciclovirHow we know
- Trial to Study Anti- HCMV Therapy in Breast Cancer Patients With Progressive Intracranial Metastases and CMV InfectionRecruitingPhase 2The Methodist Hospital Research InstituteNCT07383649Written as ValganciclovirHow we know
- CMV Immunity Monitoring in Lung Transplant RecipientsRecruitingPhase 2NYU Langone HealthNCT05708755Written as ValganciclovirHow we know
- ValgaNciclovIR for CMV Viraemia in AdvaNced HIV diseAseNot yet recruitingPhase 2Wits Health Consortium (Pty) LtdNCT07379203Written as ValganciclovirHow we know
- Efficacy and Safety of Leymovir Versus Valganciclovir in Prevention of Cytomegalovirus Infection and Cytomegalovirus Disease in Chinese Kidney Transplant RecipientsRecruitingPhase 4First Affiliated Hospital Xi'an Jiaotong UniversityNCT07266467Written as ValganciclovirHow we know
- Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease ActivityActive, not recruitingPhase 2National Cancer Institute (NCI)NCT00092222Written as ValganciclovirHow we know
- Randomized Controlled Trial of Valganciclovir for Cytomegalovirus Infected Hearing Impaired InfantsTerminatedPhase 2Albert ParkNCT03107871Written as ValganciclovirHow we know
- ANTIVIRAL TREATMENT OF CYTOMEGALOVIRUS IN DEPRESSIONCompletedPhase 1/2Laureate Institute for Brain Research, Inc.NCT04724447Written as ValganciclovirHow we know
- Phase 1 Study of GEN2 in Patients With Advanced Solid TumorsTerminatedPhase 1GenVivo, Inc.NCT06391918Written as GEN2 + ValganciclovirHow we know
- Systemic and Topical Antivirals for Control of Cytomegalovirus Anterior Uveitis: Treatment OutcomesTerminatedPhase 2/3University of California, San FranciscoNCT03586284Written as Valganciclovir HydrochlorideHow we know
- A Clinical Trial Evaluating the Efficacy of Valganciclovir in Glioblastoma PatientsActive, not recruitingPhase 2Cecilia Soderberg-NauclerNCT04116411Written as Valganciclovir TabletsHow we know
- Empirical Treatment Against Cytomegalovirus and Tuberculosis in HIV-infected Infants With Severe PneumoniaCompletedPhase 2/3Hospital Universitario 12 de OctubreNCT03915366Written as Valganciclovir Oral Solution [Valcyte]How we know
- An Open-Label Phase 2 Trial of Nanatinostat Plus Valganciclovir in Patients With EBV+ Relapsed/Refractory LymphomasTerminatedPhase 2Viracta Therapeutics, Inc.NCT05011058Written as Nanatinostat in combination with valganciclovirHow we know
- Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV+ Lymphoid MalignanciesCompletedPhase 1/2Viracta Therapeutics, Inc.NCT03397706Written as VRx-3996 and valganciclovirHow we know
- A Mass Balance Study of [14C]-Nanatinostat and Relative Bioavailability Study of Nanatinostat in Patients With Advanced CancersTerminatedPhase 1Viracta Therapeutics, Inc.NCT06302140Written as Nanatinostat (free base) tablets in combination with ValganciclovirHow we know
- Valganciclovir Therapy in Infants and Children With Congenital CMV Infection and Hearing LossCompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT01649869Written as ValganciclovirHow we know
- Comparison of Oral Valganciclovir and Placebo for the Prevention of Cytomegalovirus (CMV) After Lung TransplantationCompletedPhase 3Duke UniversityNCT00227370Written as valganciclovirHow we know
- Impact of Anti-cytomegalovirus Treatment in the Management of Relapsing Ulcerative Colitis Requiring Vedolizumab TherapyTerminatedPhase 3Centre Hospitalier Universitaire de Saint EtienneNCT04064697Written as ValganciclovirHow we know
- Clinical Trial of Efficacy and Safety of the Combination of Reduced Duration Prophylaxis Followed by Immuno-guided Prophylaxis in Lung Transplant Recipients.CompletedPhase 3Maimónides Biomedical Research Institute of CórdobaNCT03699254Written as ValganciclovirHow we know
See all 76 studies that test Valganciclovir →
Given beside what is tested · 9 — Valganciclovir is usual care or a partner of the new treatment
- Combination Letermovir and Standard of Care Antiviral for Enhanced Antiviral Response in Cytomegalovirus Infection in Lung Transplant RecipientsRecruitingPhase 4University Health Network, TorontoNCT07235683Written as Valganciclovir/GanciclovirHow we know
- Letermovir-based Dual Therapy for Treatment of Cytomegalovirus InfectionsRecruitingPhase 3Assistance Publique - Hôpitaux de ParisNCT06334497Written as ValganciclovirHow we know
- A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 With Valganciclovir (VGCV) in Subjects With GlioblastomaRecruitingPhase 1/2Rznomics, Inc.NCT06102525Written as VGCVHow we know
- EBV Lytic Reactivation Therapy Combined With PD-1 Antibody in Recurrent/Metastatic Nasopharyngeal CarcinomaNot yet recruitingPhase 2Sun Yat-sen UniversityNCT07138989Written as Valganciclovir Hydrochloride TabletsHow we know
- Nanatinostat Plus Valganciclovir in Advanced EBV+ Solid Tumors and in Combination With Pembrolizumab in EBV+ RM-NPCTerminatedPhase 1Viracta Therapeutics, Inc.NCT05166577Written as ValganciclovirHow we know
- Tocilizumab for KSHV-Associated Multicentric Castleman DiseaseCompletedPhase 2National Cancer Institute (NCI)NCT01441063Written as Valganciclovir (VGC)How we know
- Cytogam Administration in Abdominal Organ Transplant Recipients at High Risk for Cytomegalovirus InfectionCompletedPhase 4Medical University of South CarolinaNCT01509404Written as ValganciclovirHow we know
- Steroid-Free Versus Steroid-Based Immunosuppression in Pediatric Renal (Kidney) TransplantationCompletedPhase 1/2National Institute of Allergy and Infectious Diseases (NIAID)NCT00141037Written as ValganciclovirHow we know
- Study of HQK-1004 and Valganciclovir to Treat Epstein-Barr Virus (EBV) - Positive Lymphoid Malignancies or Lymphoproliferative DisordersTerminatedPhase 2HemaQuest Pharmaceuticals Inc.NCT00992732Written as Valganciclovir (may substitute with ganciclovir)How we know
As the comparator · 8 — what is tested is compared with Valganciclovir
- Valganciclovir vs. Letermovir for CMV Prophylaxis in Heart TransplantRecruitingPhase 2/3Columbia UniversityNCT07079735Written as ValganciclovirHow we know
- Is Valacyclovir Non-inferior to Valganciclovir as CMV and EBV Prophylaxis in Kidney Transplant Recipients? A Single-Center Prospective Randomized Pilot StudyRecruitingNot applicableNational Taiwan University HospitalNCT07294547Written as Valganciclovir (Valcyte)How we know
- Maribavir vs. Valganciclovir for CMV Prophylaxis in High-Risk Kidney Transplant RecipientsCompletedPhase 4Medical University of South CarolinaNCT06034925Written as ValganciclovirHow we know
- Letermovir for CMV Prevention After Lung TransplantationCompletedPhase 2Fernanda P Silveira, MD, MSNCT05041426Written as ValganciclovirHow we know
- Letermovir Versus Valganciclovir to Prevent Human Cytomegalovirus Disease in Kidney Transplant Recipients (MK-8228-002)CompletedPhase 3Merck Sharp & Dohme LLCNCT03443869Written as ValganciclovirHow we know
- A Study of Maribavir Compared to Valganciclovir to Treat Cytomegalovirus Infections in People Who Have Received Stem Cell TransplantsCompletedPhase 3ShireNCT02927067Written as ValganciclovirHow we know
- ValGanciclovir Versus ValAcyclovir for Viral Prophylaxis in Kidney TransplantationCompletedPhase 2University of MinnesotaNCT01972035Written as ValganciclovirHow we know
- Efficacy and Safety Study of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or CidofovirCompletedPhase 3ShireNCT02931539Written as ValganciclovirHow we know
Codes
What other systems call Valganciclovir · ClinicalTrials.gg INT006757
- MeSH (NLM) D000077562ValganciclovirConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) GCU97FKN3RVALGANCICLOVIRConfirmed FDA, NLM, Wikidata
- RxNorm 275891Confirmed FDA, Wikidata
- Wikidata Q423384valganciclovirConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C2629ValganciclovirConfirmed FDA, Wikidata
- DrugBank DB01610One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000077562 | Valganciclovir | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | GCU97FKN3R | VALGANCICLOVIR | Confirmed FDA, NLM, Wikidata |
| RxNorm | 275891 | — | Confirmed FDA, Wikidata |
| Wikidata | Q423384 | valganciclovir | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C2629 | Valganciclovir | Confirmed FDA, Wikidata |
| DrugBank | DB01610 | — | One source Wikidata |
Also registered as valganciclovir hydrochloride (UNII 4P3T9QF9NZ · RxNorm 283815).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.